Researchers Database

HAMANO Takayuki

    Professor
Last Updated :2026/03/10

Researcher Information

J-Global ID

Research Areas

  • Life sciences / Nephrology

Published Papers

Books etc

  • 腎臓内科レジデントマニュアル 改訂第8版
    濱野高行 (Joint work)診断と治療社 2019/02
  • 患者さんとご家族のためのCKD療養ガイド2018
    濱野高行 (Joint work)東京医学社 2018/12
  • 腎臓専門医のためのCKD診療 Q&A
    濱野高行 (Joint work)東京医学社 2018/11
  • 骨粗鬆症診療 -骨脆弱性から店頭骨折防止の治療目標へ-Total Careの重要性
    濱野高行 (Joint work)医薬ジャーナル社 2018/10
  • 濱野, 高行; 藤井, 秀毅; 風間, 順一郎; 深川, 雅史 日本メディカルセンター 2018/09 9784888753081 319p
  • CKD-MBD 3rd Edition
    濱野高行; 岡 樹史; 山口 慧 (Joint work)日本メディカルセンター 2018/09
  • エビデンスに基づくCKD診療ガイドライン2018
    濱野高行 (Joint work)東京医学社 2018/06
  • CKD・透析に併発する運動器疾患 内科・整形外科による多角的アプローチ
    濱野高行 (Joint work)医薬ジャーナル社 2018/05
  • 腎と透析 ベッドサイド検査事典
    濱野高行 (Joint work)東京医学社 2018/05
  • 透析療法ネクストXXⅣ エテルカルセチド SHPT治療の次なるステージへ
    濱野高行 (Joint work)医学図書出版 2018/05
  • 今日の治療方針 2018年版 -私はこうして治療している
    濱野高行 (Joint work)医学書院 2018/01
  • こんな時どうすれば!? 透析患者の内科管理コンサルタント
    濱野高行 (Joint work)金芳堂 2017/12
  • 透析療法ネクストXXⅡ 高リン血症治療の新たな選択肢 -スクロオキシ水酸化鉄の果たす役割-
    濱野高行 (Joint work)医学図書出版 2017/11
  • リンの事典
    濱野高行 (Joint work)朝倉書店 2017/11
  • レジデントのための腎臓病診療マニュアル
    濱野高行 (Joint work)医学書院 2017/11
  • 第61回日本透析医学会開催記念「よくわかるシリーズ」透析療法必須知識
    濱野高行 (Joint work)東京医学社 2017/06
  • 今日の治療方針2017年 私はこう治療している
    濱野高行 (Joint work)医学書院 2017/01
  • 腎疾患・透析 最新の治療 2017-2019
    岡 樹史; 濱野高行 (Joint work)南江堂 2017/01
  • Annual Review 腎臓 2016
    松井 功 (Joint work)中外医学社 2016/01 9784498224247

MISC

Research Grants & Projects

  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2025/04 -2028/03 
    Author : 難波 倫子; 猪阪 善隆; 野々村 祝夫; 土井 洋平; 角田 洋一; 濱野 高行; 中澤 成晃
  • 日本学術振興会:科学研究費助成事業
    Date (from‐to) : 2025/04 -2028/03 
    Author : 濱野 高行; 西山 成; 難波 倫子; 北田 研人; 村島 美穂; 水野 晶紫
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2022/04 -2025/03 
    Author : 難波 倫子; 猪阪 善隆; 山中 和明; 野々村 祝夫; 水井 理之; 土井 洋平; 今村 亮一; 濱野 高行; 阿部 豊文
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2021/04 -2024/03 
    Author : 濱野 高行; 村島 美穂; 安部 賀央里
     
    当院で2018年から2020年までの間に抗癌剤治療を受けた2644名の後方視的観察研究を行った。eGFRが前回のeGFRに比して30%以上低下するものをAKIと定義して、AKIに関連する抗がん剤をまずは見だした。平均年齢は65歳で平均eGFR は71 (59-84) mL/min/1.73m2であった。Pembrolizumab, trastuzumabと oxaliplatinがAKIと関連し、そのオッズ比(95%信頼区間)はそれぞれ 1.52 [1.03-2.23], 2.78 [1.26-6.12],1.72 [1.20-2.46]であった。 抗癌剤以外のリスク因子は高いCRPとループ利尿薬やトルバプタン、抗血小板薬の使用であった。PembrolizumabやtrastuzumabとAKIの関連はNSAIDs使用患者で特に強かった。 抗腫瘍薬による電解質異常を早期に捕捉できるようにするため、2021年5月から当院で電子カルテ上で自動的に各科主治医に腎臓内科受診を促す「電解質バスターズ」なるシステムを構築した。実際に依頼を行うかどうかは担当医師の判断にゆだねた。紹介基準はNa<125, Na>160, K<2.5, K>6.0, 補正Ca<7.5, 補正Ca>11.5, Mg<1.0, Mg>4.0 mEq/Lとした。電解質バスターズ導入前後6か月の依頼箋数を比較したところ、K異常は導入前後で紹介数は変わらなかったが、Na, Ca, Mg異常は各々2倍に増え、3つの電解質異常をまとめると依頼のincident rate ratioは2.01(95% CI: 1.00-4.24)となった。依頼の最も多い低Na血症16例のうち、5例がSIADH、5例が薬剤性(抗癌剤や利尿剤)を含む腎性Na喪失、3例が水中毒と診断され、SIADHの2例にトルバプタンを導入しNa濃度が改善した。
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2019/04 -2022/03 
    Author : Tomoko Namba
     
    We enrolled 195 living donors of kidney transplantations conducted between 2010 and 2016 in two facilities. Outcome of this study was reaching eGFR less than 45 mL/min/1.73m2 within 4 years after donation. To explore the cut-off point of eGFR reduction rate at 30 days after donation (POD30 eGFR reduction) predicting the outcome with the highest Youden Index, receiver operating characteristic (ROC) analyses were performed followed by multivariate logistic regression analyses. As a time to event analyses, we employed a Cox regression model adjusting for sex, age, eGFR at baseline. The results of these analyses indicate that eGFR reduction rate at 30 days after donation may be a good predictor of long-term renal function among kidney donors.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2018/04 -2021/03 
    Author : HAMANO TAKAYUKI
     
    Not only in congestive heart failure with congestive kidney (CK), but also in nephrotic syndrome with CK, we found elevated serum ADH levels together with high osmolarity of the urine. As compared to nephrotic syndrome without CK, the urine Na/K of the patients with nephrotic syndrome accompanied by CK (defined as >19% reduction in total kidney volume after the therapy) was significantly higher and SUSPPAP was lower. This finding suggests that sodium retention of nephrotic syndrome with CK is partly mediated by RAAS activation. We reported a case with a severe nephrotic syndrome which was resolved completely by massive fluid removal by diuretics and ARB. This case relapsed after high salt intake. Given that enhanced RAAS activation increase the expression of SGLT2 on proximal tubules leading to sodium retention further, administration of SGLT2 might be promising also in nephrotic syndrome with CK.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
    Date (from‐to) : 2017/04 -2019/03 
    Author : Namba Tomoko; Isaka Yoshitaka; Takabatake Yoshitsugu; Hamano Takayuki
     
    We generated symptomatic Fabry disease mice (Fabry mice) with proteinuria and histological alterations. On electron microscopy,more accumulation of lamellated lipid inclusions called zebra bodies were observed in tubular epithelial cells than in podocytes. Fabry mice showed lower expression of megalin in proxymal tubular cells, compared to control mice. We confirmed that administration of active vitamin D with enzyme decreased proteinuria of Fabry mice. Renal manifestations of 7-month-old Fabry mice were so weak that we need longer observational period to evaluate treatment effects of active vitamin D.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2015/04 -2018/03 
    Author : HAMANO TAKAYUKI
     
    Phosphate loading for short duration repressed EPO production in the kidney, however did not induce anemia. Phosphate loading for long duration induced anemia, but at the same time, brought about renal fibrosis. These findings might indicate that phosphate loading induce renal anemia, but does not support our hypothesis of “phosphate-driven anemia” that phosphate loading per se induce anemia not by worsening renal function. Abandoning our prior hypothesis, we moved on to the next question if phosphate loading shorten the lifespan of rodents. To address this question, we administered a phosphate binder, lanthanum carbonate, to mice for nearly two years. We found that adding 3.0 % lanthanum carbonate to chow lengthened the survival time only in male mice. Observed better renal function of mice fed lanthanum carbonate might be the reason for improved survival. We will elucidate the mechanisms of renoprotection by phosphate restriction.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2014/04 -2017/03 
    Author : Matsui Isao
     
    Effects of 25(OH)D3 on unilateral ureteral obstruction were analyzed. Excess 25(OH)D3 in obstructed mice worsened oxidative stress and tubulointerstitial fibrosis, whereas moderate levels of 25(OH)D3 had no effects. The exacerbating effects of excess 25(OH)D3 were abolished in CYP27B1/VDR double-knockout mice and in macrophage-depleted CYP27B1 knockout mice. Excess 25(OH)D3 upregulated both M1 marker (TNF-α) and M2 marker (TGF-β1) levels of kidney-infiltrating macrophages. In vitro analyses verified that excess 25(OH)D3 directly upregulated TNF-α and TGF-β1 in cultured macrophages but not in tubular cells. TNF-α and 25(OH)D3 cooperatively induced oxidative stress by upregulating iNOS in tubular cells. Aggravated tubulointerstitial fibrosis in mice with excess 25(OH)D3 indicated that macrophage-derived TGF-β1 also had a key role in the pathogenesis of surplus 25(OH)D3. Thus, excess 25(OH)D3 worsens tubulointerstitial injury by modulating macrophage phenotype.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Research Activity Start-up
    Date (from‐to) : 2012/08 -2014/03 
    Author : HAMANO Takayuki
     
    In recruiting patients, the anemia in Japanese renal transplant patients proved to be mild unlike the counterparts in the western countries and we found relatively low percentage of patients meeting the enrollment criteria. Therefore, we began to enroll patients in new facilities in addition to planned facilities. The baseline results of 96 patients enrolled so far are as follows. Mean dialysis vintage prior to transplantation was 6 years, mean creatinine was 1.96 mg/dL, and mean hemoglobin was 11.0 g/dL. Half of the patients received long-acting ESA. Mean ferritin was 149 ng/mL and TSAT was 36% possibly due to the fact that iron repletion is the enrollment criteria. As a result of enrolling relatively severe anemia, mean urinary protein was 0.99 g/gCr, which is much higher than expected. We are still enrolling patients while we are doing intervention in enrolled patients.
  • 日本学術振興会:科学研究費助成事業 若手研究(B)
    Date (from‐to) : 2006 -2007 
    Author : 濱野 高行
     
    アデニン腎不全モデルラットは腎機能の低下に伴い血管石灰化が高度になり、Fetuin-Aの肝臓での産生が著しく低下した。しかし血中でのFetuin-Aの低下は非常に軽微であった。ここで我々はFetuinmineralcomplex(FMC)に注目し、各血清を遠心処理することで分離可能な血中FMCが、腎機能低下に伴い徐々に増加していることを、質量分析を用いることでつきとめた。腎不全における血管石灰化に対して血中FMCは重要な役割を果たしていることが予想され、引き続き石灰化とFMCの関係を明らかにすべく、アデニンラットにalendronateによる治療介入を行った。すると治療群では有意に血管石灰化が改善したが、肝臓でのfetuin-Aの産生も血中のtotalfetuin-A濃度にも差を認めなかった。しかし治療群においては、血清中のtotalfetuin-AのうちFMCの占める割合は非治療群に比し著しく減少していた。つまり血管石灰化ストレス下では、血中のFeuin-Aは石灰化の担体であるCa,リン,Mgを取り込むことでFMCを形成し血管石灰化に対して保護的に働いている可能性が示された。腎不全のヒト血清においても、ラットと同様の方法でFMCを分離することに我々は成功した。さらにELISAによる血中Fetuin-A濃度の検討では血清を遠心することで濃度が有意に低下しており、ヒトELISAkitはFMCとそれ以外のfreeのFetuin-Aをともに測定していることが分かった。約100名の保存期糖尿病性腎症の患者では、冠状動脈石灰化指数は、totalfetuin-Aの濃度とは全く有意な関係はなかったが、FMCとは有意な正の相関、freefetuin-A濃度とは有意な負の相関関係があった。このことより、fetuin-Aの存在様式をみることで、血管石灰化ストレスを評価できることが示唆された。


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.